Related Experiment Video
Updated: Aug 19, 2026

A Refined Aerosol-Based Intratracheal Bleomycin Delivery Method for Reproducible and Minimally Invasive Mouse Models of Pulmonary Fibrosis
Published on: January 16, 2026
[Rat alveolar type II injured by bleomycin]
Lu Kong1, Zhi-gang Wang, Jian-zhao Niu
1Laboratory of Cell Biochemistry, Beijing University of Chinese Medicine, Beijing 100029, China.
Objective:
To explore dysfunction mechanism of rat alveolar type II (AT-II) injured by bleomycin (BLM).
Methods:
SD rats were injected with a single intratracheal dose of bleomycin or control saline. On day 7, 14, and 28 following intratracheal bleomycin or saline instillation, animals were killed under overdose of 1.5% sodium pentobarbital (0.25 ml/100 g, i.p.) and bronchoalveolar lavage fluid (BALF) from the lung was tested for the activity of pulmonary surfactant (PS) by the Whihelmy Film Balance. Several concentrations of bleomycin stimulated the culture of rat AT-II cells, and surfactant protein (SP) A, B, and aquaporin-1 (AQP) mRNA were analyzed by fluorescent quantitative polymerase chain reaction (FQ-PCR).
Results:
The activity of PS and hypoxemia significantly decreased on day 7 and improved on day 14 and completely recovered to normal status on day 28. SP-A, B, and AQP-1 mRNA expression in BLM-stimulated group were significantly lower than those in the control group (P<0.001).
Conclusion:
BLM-injured AT-II cells decrease the levels of SP-A, B, and AQP-1 mRNA and cause PS dysfunction, resulting in hypoxemia and pneumonedema.
Related Concept Videos
Chronic Obstructive Pulmonary Disease II: Emphysema
Atelectasis II: Pathophysiology
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Pneumothorax II: Pathophysiology
Acute Respiratory Failure-III
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History:

